Skip to Content
Merck
CN
  • Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature.

Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature.

Chest (1998-03-14)
P W Wong, N Macris, L DiFabrizio, N S Seriff
ABSTRACT

A 69-year-old man with advanced prostate cancer was receiving antiandrogen therapy (bicalutamide [Casodex]). He developed dyspnea, peripheral eosinophilia and bilateral pulmonary interstitial infiltrates. Transbronchial biopsy confirmed pulmonary eosinophilia. Withdrawal of bicalutamide and initiation of steroid therapy resulted in clinical improvement.

MATERIALS
Product Number
Brand
Product Description

Bicalutamide, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Bicalutamide (CDX), ≥98% (HPLC), powder
Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard